Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma Preliminary results of a phase I/II clinical trial

Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma : Preliminary results of a phase I/II clinical trial

Copyright © 2022. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 238(2022) vom: 01. Mai, Seite 108992
Auteur principal: Cheng, Xiaobo (Auteur)
Autres auteurs: Wang, Jing, Qiu, Chenli, Jin, Yanling, Xia, Bili, Qin, Ran, Hu, Huiliang, Yan, Jia, Zhang, Xiaoyan, Xu, Jianqing
Format: Article en ligne
Langue:English
Publié: 2022
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't Immunotherapy Lung adenocarcinoma Natural killer T-cells Antineoplastic Agents, Immunological Immunologic Factors Programmed Cell Death 1 Receptor
Accès en ligne Volltext